Kronos Bio: Clinical Trials

2 trials sponsored by Kronos Bio, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Terminated 2
Phase 22Terminated 2

Follow Kronos Bio: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedKronos Bio242022-08-052024-08-07
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
KB-0742 - Relapsed Solid Tumors, Refractory Solid Tumors
Phase 1 / Phase 2TerminatedKronos Bio1352021-02-082025-02-17

Conditions studied

Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)

Interventions

gilteritinib (1)

Countries

Spain (2)  ·  United States (2)  ·  United Kingdom (1)

NIH funding

2023 (1)